rosiglitazone has been researched along with angiotensin i in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Mehta, JL; Molavi, B | 1 |
| Cui, M; Han, CJ; Li, M; Liu, JT; Liu, XF; Mao, JJ; Pang, XM | 1 |
2 other study(ies) available for rosiglitazone and angiotensin i
| Article | Year |
|---|---|
Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK.
Topics: Angiotensin I; Angiotensin II; Animals; Blood Glucose; Cardiotonic Agents; Enzyme Inhibitors; Hemodynamics; Hypoglycemic Agents; Immunohistochemistry; Ligands; Male; Mitogen-Activated Protein Kinase 1; Myocardial Infarction; Myocardium; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2006 |
Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway.
Topics: Angiotensin I; Angiotensin II; Anti-Inflammatory Agents; Aorta; C-Reactive Protein; Cells, Cultured; Endothelial Cells; Humans; Mitogen-Activated Protein Kinases; PPAR gamma; Reactive Oxygen Species; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2012 |